Kiniksa Pharmaceuticals, Ltd.
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Kiniksa Pharmaceuticals, Ltd. generated cash of $13,301,000, which is more than the previous year. Cash used in financing activities reached the amount of $1,495,000 last year. Net change in cash is therefore -$14,761,000.
Cash Flow
| 2016 | -21.86M | -3K | 42.50M |
|---|---|---|---|
| 2017 | -50.21M | -69K | 39.87M |
| 2018 | -81.01M | -239.19M | 346.73M |
| 2019 | -158.36M | 49.21M | 84.10M |
| 2020 | -136.53M | -23.44M | 227.08M |
| 2021 | -126.29M | 128.63M | 5.88M |
| 2022 | 5.80M | -8.07M | 2.51M |
| 2023 | 13.30M | -29.55M | 1.49M |
KNSA Cash Flow Statement (2016 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 122.71M | 122.47M | 114.24M | 47.13M | 72.18M | 45.66M | 56.07M | 35.43M |
Operating activities | ||||||||
Net income | 14.08M | 183.36M | -157.92M | -161.38M | -161.86M | -103.22M | -64.87M | -23.97M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||
Depreciation and amortization | 2.34M | 2.40M | 2.35M | 2.40M | 2.06M | 286K | 28K | 22K |
Stock-based compensation expense | 27.14M | 25.12M | 25.17M | 20.87M | 15.08M | 0 | 897K | 368K |
| Deferred income tax benefit | 27.14M | 25.12M | 25.17M | 20.87M | 15.08M | 0 | 897K | 368K |
| Changes in operating assets and liabilities: | ||||||||
Accounts receivable, net | -950K | -8.67M | -3.91M | 0 | 0 | 0 | 0 | 0 |
Inventories | -9.52M | -17.92M | -3.67M | 0 | 0 | 0 | 0 | 0 |
Accounts payable | 347K | 6.03M | 1.36M | -4.96M | -4.70M | 8.82M | 1.00M | 119K |
Cash generated by operating activities | 13.30M | 5.80M | -126.29M | -136.53M | -158.36M | -81.01M | -50.21M | -21.86M |
Investing activities | ||||||||
Purchases Of Investments | -204.93M | -135.86M | -157.25M | -430.21M | -488.77M | -402.00M | 0 | 0 |
Investments In Property Plant And Equipment | -130K | -105K | -20.41M | -283K | -3.20M | -5.29M | -69K | -3K |
Acquisitions Net | 0 | 91K | 20M | 23.16M | -52.41M | 0 | 0 | 0 |
Cash generated by investing activities | -29.55M | -8.07M | 128.63M | -23.44M | 49.21M | -239.19M | -69K | -3K |
Financing activities | ||||||||
Common Stock Issued | 0 | 3.41M | 5.88M | 227.08M | 83.10M | 159.19M | 39.87M | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | -2.20M | -901K | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | 1.49M | 2.51M | 5.88M | 227.08M | 84.10M | 346.73M | 39.87M | 42.50M |
Net Change In Cash | -14.76M | 245K | 8.22M | 67.11M | -25.04M | 26.52M | -10.41M | 20.63M |
Cash at end of period | 107.95M | 122.71M | 122.47M | 114.24M | 47.13M | 72.18M | 45.66M | 56.07M |
| Data source | Data source | Data source | Data source | Data source | Data source |